Navigation Links
Codexis Names David Anton VP Bioindustrials R&D
Date:3/25/2008

REDWOOD CITY, Calif., March 25 /PRNewswire/ -- Codexis, Inc., today announced the appointment of David Anton, Ph.D. to the newly-created position of Vice President, Bioindustrials Research and Development. He joins Codexis from DuPont, where he was Venture Manager, Biofuels. He will report to Alan Shaw, Ph.D., President and CEO.

"Codexis targets major global energy and environmental markets where clean technology can make a significant impact," said Alan Shaw, Ph.D., President and CEO. "We are currently working with Shell in the development of biofuels, and expect to apply our technology to other potential new bioindustrial applications, such as carbon capture and storage, waste water purification and cleaner chemical manufacturing."

"Dr. Anton has over 25 years experience directing the development of new technology solutions and production processes at one of the world's largest science companies," Dr. Shaw added. "His experience as a scientist and venture manager in bioindustrials can make an important, immediate contribution to this important Codexis business. We are pleased to expand our management team with such a well known and broadly-experienced research executive."

Dr. Anton joined DuPont in 1983 and held a variety of senior research management positions across bioprocessing and biocatalysis. He led the process research, development and commercialization of several products, including 1,3 propanediol (a chemical intermediate used in a variety of industrial applications ranging from airplane deicing fluids to textiles and carpet). As Vice President, Research and Development for DuPont's joint venture with Tate and Lyle, he directed technology start-up activities for the first 100 million-pound plant for 1,3 propanediol, commissioned in Loudon, TN in 2006. As Venture Manager, Biofuels, he was global business lead for development of DuPont's advanced biofuel, biobutanol.

He holds a bachelor's degree in biochemistry from the University of California, Berkeley, and a Ph.D. in biochemistry from the University of Minnesota. He is a member of the joint DOE/USDA Biomass Research and Development Technology Advisory Committee.

Codexis, Inc., a clean technology company, is a leading developer of biocatalytic process technologies that can substantially reduce the cost of manufacturing across a broad range of industries. These technologies enable novel solutions for efficient, cost-effective and environmentally-friendly processes for pharmaceutical, energy and industrial chemical applications. In 2006, the U.S. EPA recognized Codexis with a Presidential Green Chemistry Challenge Award. Codexis is a registered trademark of Codexis, Inc. For more information, please visit http://www.codexis.com.

Contact: Justin Jackson, jjackson@burnsmc.com, Burns McClellan, 212-213-0006, or Lyn Christenson, lyn.christenson@codexis.com, 650-421-8144.


'/>"/>
SOURCE Codexis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Codexis Launches Codex(TM) MicroCyp Platform to Produce Drug Metabolites and Novel Lead Compounds
2. Rothwell, Wolf Elected to Codexis Board
3. Codexis Opens Singapore Laboratory
4. Bruce Pasternack Elected to Codexis Board
5. Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
6. Codexis Appoints Singapore Laboratories Managing Director
7. ThermoGenesis Names Dr. Mahendra Rao to Board of Directors
8. Cato Research Names John Cline as President
9. Pathway Medical Technologies Names Paul Buckman Chairman of the Board of Directors
10. Onyx Pharmaceuticals Names N. Anthony Coles, M.D. as President, Chief Executive Officer and Member of its Board of Directors
11. 5AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... ... January 12, 2017 , ... ... treatments, 26-year-old Lisa Rosendahl’s doctors gave her only a few months to live. ... drug combination that has stabilized Rosendahl’s disease and increased both the quantity and ...
(Date:1/12/2017)... 2017   Protein Sciences Corporation , a ... Flublok Influenza Vaccine ®, announced today that its ... safety results and induced strong neutralizing antibodies against ... is expected to advance into human clinical trials ... Institute of Technology in Immunobiologicals of the Oswaldo ...
(Date:1/12/2017)... 12, 2017 The report "Direct-Fed Microbials Market by Type (Lactic Acid ... Liquid), and Region - Global Forecast to 2022", published by MarketsandMarkets, the global ... projected to reach USD 1,399.6 Million by 2022, at a CAGR of 6.96% ... ... MarketsandMarkets Logo ...
(Date:1/11/2017)... ... January 11, 2017 , ... ... Cancer Research show early promise of the investigational anti-cancer agent tucatinib (formerly ONT-380) ... 5 previous treatment regimens. Twenty-seven percent of these heavily pretreated patients saw clinical ...
Breaking Biology Technology:
(Date:1/12/2017)... -- New research undertaken by Fit Small Business has ... were simply asked which office technology had they not used ... issue.  Insights on what will be key features ... and industry leaders including Penelope Trunk , Martin ... Some of these findings included; ...
(Date:1/6/2017)... , Jan. 5, 2017  SomaLogic announced today ... Life Alliance" established by iCarbonX, the ... build a "Global Digital Health Ecosystem that can ... combination of individual,s biological, behavioral and psychological data, ... between the companies, SomaLogic will provide proteomics data ...
(Date:12/22/2016)... , Dec. 20, 2016  As part of its ... the leading personal genetics company, recently released its latest children,s ... . The book focuses on the topics of inheritance and ... Science Standards (NGSS) taught in elementary school classrooms in the ... a series by illustrator Ariana Killoran , whose previous ...
Breaking Biology News(10 mins):